-

Bayer Strengthens Company’s Government and Industry Affairs Group in Key U.S. Market with Two Appointments

Michael Parrish Named Vice President of Public Affairs, Science and Sustainability in the U.S.

Duane Simpson Named Vice President of North America Crop Science Public Affairs, Science and Sustainability

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the appointment of Michael Parrish to the position of Vice President of Public Affairs, Science and Sustainability, U.S. Parrish has served as the interim lead of U.S. Public Affairs since April 2021, following the function’s formation. In this new role, he will be responsible for driving a unified organization and strategy, including oversight of the company’s U.S. Government Relations, Policy and Corporate Engagement teams.

To continue to align and unify our efforts with policymakers at the state and federal levels, government relations for Crop Science will now shift to the U.S. Public Affairs, Science and Sustainability team, bringing our three divisional government affairs efforts to one team representing Bayer. In this capacity, the company has promoted Duane Simpson to Vice President of the North America Crop Science Public Affairs, Science and Sustainability Team. Simpson and his team will be responsible for engaging with key federal and state agencies, as well as industry and trade associations, that help govern the technologies that farmers use and support the growth of the U.S. and Canadian agriculture sectors.

Parrish will continue to report to Patrick Lockwood-Taylor, President of Bayer U.S., and serve as a member of the U.S. Country Leadership Team, as well as the Global Public Affairs Leadership Team reporting to Matthias Berninger, Senior Vice President, Public Affairs and Sustainability. Simpson will report to Jacqueline Applegate, President, North America Crop Science, and continue to be a part of the Crop Science North American Leadership Team.

“As a top U.S. life sciences company, we remain focused on using our science-based innovation for better lives, and leading with heart, to make our vision of ‘Health for All, Hunger for None’ a reality for generations to come,” said Patrick Lockwood-Taylor, President of Bayer U.S. “These appointments recognize the tremendous success both Michael Parrish and Duane Simpson have already brought to Bayer. Under their leadership, the organization will continue to build and strengthen relationships with policymakers and key stakeholders that are essential to advancing our growth and value – and our success – in the company’s most important market.”

Parrish brings a wealth of experience to the role, with more than 20 years in government service and government relations in corporate settings, working with elected officials, and various roles held at the U.S. Department of State and Department of Justice. Simpson has nearly 30 years of experience in political campaigns, state government, trade associations, industry affairs and government affairs at both the state and federal level.

Parrish and Simpson assume their new responsibilities effective March 1, 2022.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.us.

Bayer U.S. Social Media Channels: Facebook / Twitter / Instagram

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Nicole Hayes, Bayer U.S.
Nicole.Hayes@bayer.com
201-421-5268

Bayer


Release Summary
Bayer Strengthens Company’s Government and Industry Affairs Group in Key U.S. Market with Two Appointments
Release Versions

Contacts

Nicole Hayes, Bayer U.S.
Nicole.Hayes@bayer.com
201-421-5268

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom